AIDS 2012 Recap: Quick HIV Treatment Research Review
Although much of AIDS 2012 focused on treatment as prevention and PrEP—and how people can get the greatest benefit from them—research on HIV treatment strategies and new and improved antiretrovirals did take the stage throughout the week-long conference.
Ben Young, MD, of TheBodyPro.com gives a quick run-down on treatment research presented at AIDS 2012, including updates on three experimental and three approved HIV drugs.
By Ben Young, MD
July 31, 2012
2012 has already brought us many changes to our strategies and options regarding the treatment of HIV. Just days ago, the U.S. Food and Drug Administration (FDA) approved tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP), the first biomedical intervention to prevent HIV infection. The FDA also approved the first at-home, over-the-counter test for HIV. The year also marks the emergence of two major themes: treatment as prevention (TasP) and the “cascade” of engagement in HIV care.
Here at the AIDS 2012 conference in Washington, D.C., there were several important oral and poster presentations on antiretroviral therapies….